Q1 FY2026 · ended Mar 31, 2026 · Revenue $751,691, +115.3% YoY · Filed May 15, 2026
Marker Therapeutics, Inc. (MRKR) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
$751,691
+115.3% vs year-ago quarter
Net income
$-1.83M
+54.5% vs year-ago quarter
Operating cash flow
$-3.72M
-97.8% vs year-ago quarter
Free cash flow
—
EPS
$-0.09
+69.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
16.67M
+28.9% vs year-ago quarter
Net cash
—
Operating margin
-304.0%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MRKR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1094038
- Former names
- TAPIMMUNE INC. (until Oct 17, 2018); TAPIMMUNE INC (until Jun 29, 2017); GENEMAX CORP (until Jun 28, 2007); EDUVERSE COM (until Jun 17, 2002)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | $751,691 | $1.1M | $1.2M | $861,184 |
| Operating income | -$2.6M | -$4.1M | -$1.9M | -$2.1M | -$5.1M |
| Net income | -$1.8M | -$3.2M | -$1.7M | -$2.0M | -$4.0M |
| Diluted EPS | -$0.09 | -$0.16 | -$0.09 | -$0.12 | -$0.29 |
| Operating cash flow | -$3.7M | -$1.4M | -$1.9M | -$2.7M | -$1.9M |
| Total assets | $14.6M | $17.4M | $19.1M | $21.7M | $14.8M |
| Total liabilities | $2.4M | $3.6M | $2.3M | $3.3M | $4.3M |
| Stockholders' equity | $12.2M | $13.8M | $16.8M | $18.4M | $10.5M |
| Cash and investments | $11.3M | $14.9M | $16.1M | $17.6M | $10.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 19, 2026 | Oct 19, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
May 4, 2026 | May 1, 2026 |
| ARS | Annual report to shareholders | Mar 20, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 19, 2026 | Mar 18, 2026 |
All 904 Marker Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.